Edition:
United States

Healthcare

JNJ.N
PFE.N
MRK.N

BRIEF-Toray Industries received FDA approval to begin clinical trials of cancer drug candidate in U.S.- Nikkei

* Toray Industries received FDA approval to begin clinical trials of cancer drug candidate in U.S. allowing testing on human patients- Nikkei Source text for Eikon: Further company coverage:

1:59pm EST

BRIEF-Pangaea Oncology invests 0.3 mln euros in diagnostic platform

* Invests 0.3 million euros ($318,330) in diagnostic platform Sistema nCounter Flex of US Nanostring Technologies Source text: http://bit.ly/2lMKSrM Further company coverage: ($1 = 0.9424 euros) (Gdynia Newsroom)

12:43pm EST

BRIEF-ViewRay receives FDA 510(k) clearance for MRIdian Linac

* Total backlog of $133.2 million as of December 31, 2016, representing 23 signed sales contracts

BRIEF-Neuron Bio to control 92.39 pct of Neol Bio

* Neuron Bio to control 92.39 percent of Neol Bio Source text: http://bit.ly/2m32gtr

11:32am EST

Trump meets insurers, promises catastrophic year for Obamacare

WASHINGTON, Feb 27 President Donald Trump told several chief executives of large insurance companies on Monday that 2017 will be a "catastrophic" year for the Affordable Care Act as he seeks to make good on a campaign promise to repeal the measure.

More From Around the Web

Healthcare
Johnson & Johnson $122.31 -0.35%
Pfizer Inc $34.28 +0.07%
Merck & Co Inc $65.85 -0.47%

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.